Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Daratumumab (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms CASTOR
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 27 Sep 2017 According to a Genmab media release, the Ministry of Health, Labor and Welfare in Japan has approved daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma. The approval is based on data from this and POLLUX trial.
    • 12 Sep 2017 Results evaluating the management of daratumumab related infusion-related reactions (IRRs) in the phase 3 studies CASTOR and POLLUX presented at the 42nd European Society for Medical Oncology Congress
    • 24 Aug 2017 Planned End Date changed from 21 Nov 2021 to 15 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top